Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224711 · ClinicalTrials.gov registry record · Phase 4
The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 2,290
- Enrollment target
NCT07224711 is a Phase 4 study that has not yet begun recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 2,290 participants.
The verdict
NCT07224711, a Phase 4 study, has not yet begun recruiting, sponsored by Vanderbilt University Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,290 participants
- Enrollment target
Study Summary
The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aims to answer are: The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS). The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).
Interventions
- DRUG Sodium Chloride 0.9%
- DRUG Lidocaine HCl 0.8% in D5W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,290 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224711
The ClinicalTrials.gov registry entry for NCT07224711 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 2,290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium Chloride 0.9% is the first listed.
NCT07224711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224711 about?
NCT07224711 is a clinical study titled "The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery". The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aim...
What is the current status of trial NCT07224711?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 2,290 participants. The study started on 2026-07-01. Estimated completion is 2028-05-30.
What interventions are being tested in trial NCT07224711?
The interventions under investigation include: Sodium Chloride 0.9% (DRUG), Lidocaine HCl 0.8% in D5W (DRUG).
Who is sponsoring clinical trial NCT07224711?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.